arrow
S

Simone Ribero

University of Turin
H指数:45
被引数:7,306

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Five-Year Real-World Effectiveness and Drug Survival of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis: A Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)

中度至重度斑块状银屑病中Tildrakizumab的五年真实世界有效性和药物生存率:一项多中心回顾性研究-IL PSO(意大利银屑病景观)

2026-11-170
OAAI
Effectiveness of Upadacitinib After Anti-IL-13 Treatment Failure in Atopic Dermatitis: A 52-Week Real-World Case Series - IL-AD (Italian Landscape Atopic Dermatitis)

抗IL-13治疗失败后乌帕替尼在特应性皮炎中的有效性:一项52周真实世界病例系列研究 - IL-AD(意大利特应性皮炎流行病学)

2026-10-220
PRE
Omalizumab Discontinuation in Chronic Spontaneous Urticaria: Effectiveness and Predictors of Response and Relapse Comparing Abrupt Cessation and Dose Spacing in a Retrospective Real-Life Study

奥马珠单抗在慢性自发性荨麻疹中的停药:一项回顾性真实世界研究比较突然停药与剂量递减对疗效、应答及复发的预测因素

2026-09-240
PRE
Patient-Level Cumulative Clinical Benefit of Brodalumab Over 52 Weeks: A Multicentre Real-World Study-IL PSO (Italian Landscape Psoriasis)

52周内布达拉木单抗在患者层面的累积临床获益:一项多中心真实世界研究-IL PSO(意大利银屑病全景)

2026-09-170
OAAI
Prevalence of Regulatory Safety Risk Factors Among Adolescents and Adults With Atopic Dermatitis Receiving Advanced Systemic Therapies: An International Real-World Study

特应性皮炎患者接受先进系统性治疗时调节性安全风险因素的流行率:一项国际真实世界研究

2026-09-120
PRE
A Real-Life, Multicenter, Retrospective Study on Epidemiological and Clinical Features of Patients With Hidradenitis Suppurativa and Concomitant Down Syndrome

一项关于 Hidradenitis Suppurativa 合并 Down 综合征患者流行病学和临床特征的回顾性、多中心、真实世界研究

2026-09-110
OA
Altersspezifisches Melanomrisiko im Zusammenhang mit melanozytären Nävi: Eine gepoolte Analyse aus dem M-SKIP-Projekt

与黑色素细胞痣相关的年龄特异性黑色素瘤风险:来自M-SKIP项目的合并分析

2026-09-080
OAAI
Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study
2026-09-010
PRE
Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS)

贝美克单抗治疗中度至重度化脓性汗腺炎的真实世界有效性与安全性:一项来自意大利化脓性汗腺炎景观(IL-HS)的多中心回顾性研究

2026-08-280
OAAI
Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study

非节段性白癜风患者外用鲁索利替尼的实世界有效性:一项860例患者多中心研究中关于复色、心理健康和生活质量结局的研究

2026-08-170
PRE
Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area

从度普利单抗转换至lebrikizumab治疗涉及头颈区域的轻中度特应性皮炎的疗效结局

2026-07-220
OAAI
Association Between pTERT Promoter Mutation Subtypes and Survival Outcomes in BRAF-Mutant Metastatic Melanoma Treated With BRAF/MEK Inhibitors: An Exploratory Study

pTERT启动子突变亚型与接受BRAF/MEK抑制剂治疗的BRAF突变型转移性黑色素瘤患者生存结局的关联:一项探索性研究

2026-07-070
PRE
Combination therapies for hidradenitis suppurativa: Narrative review of current strategies and emerging perspectives

Hidradenitis suppurativa的组合疗法:当前策略与新兴视角的叙述性综述

2026-05-200
PRE